A Phase 2 interventional study of Atacicept and Atacicept in Rheumatoid Arthritis, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 247th largest by enrollment of the 771 interventional ones that give a count, is one of 35 that started in 2006, is one of 215 in phase 2, and was the 149th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 35 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 803 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active RA as defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept
Drug: Atacicept
Drug: Atacicept
Drug: Placebo matched to atacicept
Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26
ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26
ACR50-CRP response is defined as \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26
ACR70-CRP response is defined as \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 26
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100-millimeter (mm) visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
Time frame: Week 26
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 26
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
Time frame: Week 26
Percentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 26
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range is 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Percentage of participants achieving improvement in HAQ-DI of at least 0.3 from baseline at Week 26 was reported.
Time frame: Week 26
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 26
The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was \<=5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.
Time frame: Week 26
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
Time frame: Baseline up to Week 38
| Milestone | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Started | 64 | 66 | 62 | 64 |
| Treated | 62 | 66 | 62 | 64 |
| Completed | 50 | 59 | 49 | 60 |
| Not completed | 14 | 7 | 13 | 4 |
| Withdrew: Adverse event | 2 | 3 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 |
| Withdrew: Disease progression | 1 | 1 | 0 | 0 |
| Withdrew: Other | 8 | 2 | 5 | 4 |
| Withdrew: Randomized but not treated | 2 | 0 | 0 | 0 |
ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | 29.0 | 30.3 | 27.4 | 39.1 |
ACR50-CRP response is defined as \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | 6.5 | 13.6 | 11.3 | 10.9 |
ACR70-CRP response is defined as \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | 0.0 | 6.1 | 4.8 | 0.0 |
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100-millimeter (mm) visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 26 | 9.7 ± 0.95 | 10.6 ± 0.84 | 9.7 ± 0.88 | 12.5 ± 0.84 |
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 26 | 1.6 | 6.1 | 4.8 | 4.7 |
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range is 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Percentage of participants achieving improvement in HAQ-DI of at least 0.3 from baseline at Week 26 was reported.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 26 | 47.4 | 48.8 | 55.9 | 37.5 |
The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was \<=5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 26 | 41.9 | 31.8 | 35.5 | 53.1 |
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
| participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| AEs | 41 | 49 | 42 | 46 |
| SAEs | 3 | 9 | 8 | 5 |
Collected over Baseline up to Week 38. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/62 (4.8%) | 15/62 (24.2%) |
| Atacicept 25 mg | — | 9/66 (13.6%) | 25/66 (37.9%) |
| Atacicept 75 mg | — | 8/62 (12.9%) | 16/62 (25.8%) |
| Atacicept 150 mg | — | 5/64 (7.8%) | 26/64 (40.6%) |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/62 | 2/66 | 2/62 | 0/64 |
| Hip fractureInjury, poisoning and procedural complications | 0/62 | 0/66 | 2/62 | 0/64 |
| Back painMusculoskeletal and connective tissue disorders | 1/62 | 0/66 | 0/62 | 0/64 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/62 | 0/66 | 1/62 | 0/64 |
| Femur fractureInjury, poisoning and procedural complications | 1/62 | 1/66 | 0/62 | 0/64 |
| Acute myocardial infarctionCardiac disorders | 0/62 | 0/66 | 1/62 | 0/64 |
| Angina pectorisCardiac disorders | 0/62 | 0/66 | 1/62 | 0/64 |
| Cardio-respiratory arrestCardiac disorders | 0/62 | 0/66 | 1/62 | 0/64 |
| Basedow's diseaseEndocrine disorders | 1/62 | 0/66 | 0/62 | 0/64 |
| MigraineNervous system disorders | 1/62 | 0/66 | 0/62 | 0/64 |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/62 | 12/66 | 5/62 | 3/64 |
| Upper respiratory tract infectionInfections and infestations | 4/62 | 3/66 | 0/62 | 8/64 |
| DiarrhoeaGastrointestinal disorders | 1/62 | 4/66 | 6/62 | 5/64 |
| HypertensionVascular disorders | 5/62 | 3/66 | 3/62 | 2/64 |
| Urinary tract infectionInfections and infestations | 3/62 | 4/66 | 3/62 | 5/64 |
| NauseaGastrointestinal disorders | 1/62 | 5/66 | 4/62 | 1/64 |
| NasopharyngitisInfections and infestations | 1/62 | 3/66 | 1/62 | 4/64 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/62 | 1/66 | 0/62 | 4/64 |
| ConstipationGastrointestinal disorders | 1/62 | 4/66 | 1/62 | 2/64 |
Intention-to-treat (ITT) population included all randomized participants who received at least one treatment dose.
| Age, Continuous(years) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|---|
| Mean | 53.1 ± 12.5 | 53.4 ± 13.1 | 55.3 ± 12.0 | 53.5 ± 10.1 | 53.8 ± 11.9 |
| Sex: Female, Male(Participants) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|---|
| Female | 51 | 54 | 53 | 53 | 211 |
| Male | 11 | 12 | 9 | 11 | 43 |
The record gives a start of Dec 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein